Video Experimental Relacionado
Updated: Oct 2, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Efectos hemodinámicos perjudiciales de la ciclizina en la insuficiencia cardíaca
L B Tan1, S Bryant, R G Murray
1Cardiac Department, John Radcliffe Hospital, Oxford.
Lancet (London, England)
|March 12, 1988
Resumen
La ciclizina intravenosa, un antiemético, fue estudiada en pacientes con insuficiencia cardíaca grave. Aumentó la presión arterial y las presiones de llenado, lo que sugiere que debe evitarse en casos de insuficiencia cardíaca.
Área de la Ciencia:
- Cardiología Cardiología.
- Farmacología Farmacología.
- Medicina de cuidados críticos Medicina de cuidados críticos.
Sus antecedentes:
- La ciclizina es un antiemético comúnmente administrado con opioides.
- Su uso se observa en pacientes con insuficiencia ventricular izquierda e infarto de miocardio.
- Los efectos hemodinámicos en la insuficiencia cardíaca grave no se comprenden bien.
Objetivo del estudio:
- Para investigar los efectos hemodinámicos de la ciclizina intravenosa.
- Para evaluar su impacto en pacientes con insuficiencia cardíaca grave.
Principales métodos:
- Estudió a 11 pacientes diagnosticados con insuficiencia cardíaca grave.
- Se administró ciclizina intravenosa y se monitorearon los parámetros hemodinámicos.
Principales resultados:
- La ciclizina elevó significativamente la presión arterial sistémica y pulmonar.
- También aumentó las presiones de llenado ventriculares derecha e izquierda.
- El fármaco contrarrestó los efectos venodilatadores de la diamorfina.
Conclusiones:
- La ciclizina intravenosa afecta negativamente la hemodinámica en la insuficiencia cardíaca grave.
- Su uso en pacientes con insuficiencia cardíaca está fuertemente desaconsejado.
- Los médicos deben evitar la ciclizina en esta población de pacientes.
Videos de Conceptos Relacionados
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...